A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Item 1. Business This Annual Report on Form 10-K contains statements of a forward-looking nature relating to future events or our future financial performance. These statements are only predictions and actual events or results may differ materially. In evaluating such statements, you should carefully consider the various factors identified in this report that could cause actual results to differ materially from those indicated in any forward-looking statements, including those set forth in “Risk Factors” in this Annual Report on Form 10-K. See “Cautionary Note Regarding Forward Looking Statements.” Our Business Overview We are a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. We maintain two active business segments: Specialized BioTherapeutics and Public Health Solutions.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | 839K | - | - | - |
| Net Income | -11M | -8.3M | - | -14M | -13M | -18M |
| EPS | $-3.44 | $-4.98 | $-12.66 | $-76.96 | $-75.04 | $-153.60 |
| Free Cash Flow | 0 | -8.4M | -8.6M | -13M | -12M | -11M |
| ROIC | -84.5% | -83.2% | - | -78.8% | -96.5% | -73.8% |
| Gross Margin | - | - | 11.6% | - | - | - |
| Debt/Equity | 0.00 | 0.00 | 0.40 | -0.00 | 1.51 | 0.02 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -12M | -9.4M | -7.7M | -14M | -13M | -19M |
| Operating Margin | 0.0% | - | -917.1% | - | - | - |
| ROE | -147.0% | -249.0% | - | - | -117.1% | -472.7% |
| Shares Outstanding | 10M | 2M | 3M | 1M | 0M | 0M |
| Metric | 2019 | 2020 | 2021 | 2022 | |||
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 3.2M | N/A | N/A | N/A | 839K | N/A | 0 |
| Gross Margin | 33.0% | N/A | N/A | N/A | 11.6% | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -11M | -19M | -13M | -14M | -7.7M | -9.4M | -12M |
| Op. Margin | -327.8% | N/A | N/A | N/A | -917.1% | N/A | 0.0% |
| Net Income | N/A | -18M | -13M | -14M | N/A | -8.3M | -11M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||
| ROIC | N/A | -73.8% | -96.5% | -78.8% | N/A | -83.2% | -84.5% |
| ROE | N/A | -472.7% | -117.1% | N/A | N/A | -249.0% | -147.0% |
| ROA | N/A | -88.9% | -46.7% | -96.6% | N/A | -88.1% | -98.9% |
| Cash Flow | |||||||
| Op. Cash Flow | -7.5M | -11M | -12M | -13M | -8.6M | -8.4M | -9.8M |
| Free Cash Flow | -7.5M | -11M | -12M | -13M | -8.6M | -8.4M | 0 |
| Owner Earnings | -7.9M | -12M | -12M | -13M | -9.0M | -8.7M | -10M |
| CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Maint. CapEx | 54K | 62K | 34K | 25K | 7K | 6K | 6K |
| Growth CapEx | N/A | N/A | N/A | N/A | N/A | N/A | 0 |
| D&A | 54K | 62K | 34K | 25K | 7K | 6K | 6K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 376K | 410K | 362K | 333K | 370K | 330K | 330K |
| Debt Repayment | 132K | 656K | 46K | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||
| Net Debt | N/A | -19M | N/A | -13M | -7.4M | -7.8M | -11M |
| Cash & Equiv. | N/A | N/A | N/A | N/A | N/A | N/A | 11M |
| Long-Term Debt | N/A | 93K | N/A | 0 | 1.0M | 0 | N/A |
| Debt/Equity | 4.34 | 0.02 | 1.51 | 0.00 | 0.40 | 0.00 | 0.00 |
| Interest Coverage | N/A | -540.2 | -31.1 | -17.3 | -156.7 | -44.1 | -44.1 |
| Equity | 1.5M | 3.7M | 11M | -2.5M | 2.5M | 4.1M | 7.6M |
| Total Assets | 7.8M | 20M | 27M | 14M | 9.8M | 9.0M | 11M |
| Total Liabilities | 6.3M | 16M | 16M | 17M | 7.3M | 4.8M | 3.7M |
| Intangibles | 39K | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -176M | -193M | -206M | -220M | -226M | -234M | -234M |
| Working Capital | 1.2M | 13M | 20M | -2.7M | 3.4M | 4.0M | 4.0M |
| Current Assets | 7.5M | 19M | 27M | 14M | 9.5M | 8.8M | 8.8M |
| Current Liabilities | 6.3M | 6.1M | 6.3M | 17M | 6.2M | 4.8M | 4.8M |
| Per Share Data | |||||||
| EPS | -115.20 | -153.60 | -75.04 | -76.96 | -12.66 | -4.98 | -3.44 |
| Owner EPS | -47.62 | -103.57 | -72.56 | -19.77 | -2.85 | -5.26 | -1.00 |
| Book Value | 8.74 | 32.49 | 64.11 | -3.76 | 0.80 | 2.48 | 0.75 |
| Cash Flow/Share | -45.03 | -99.47 | -70.19 | -19.23 | -2.73 | -5.06 | -1.11 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 0.2M | 0.1M | 0.2M | 0.7M | 3.2M | 1.7M | 10.1M |
| Valuation | |||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | -0.3 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 39.0 | 9.7 | 2.8 | N/A | 13.6 | 1.2 | 1.5 |
| Price/Sales | 11.7 | N/A | N/A | N/A | 108.2 | N/A | N/A |
| FCF Yield | -13.2% | -31.4% | -39.0% | -20.0% | -25.1% | -175.2% | N/A |
| Market Cap | 57M | 36M | 30M | 63M | 34M | 4.8M | 12M |
| Avg. Price | 225.81 | 483.68 | 288.28 | 155.73 | 28.78 | 6.18 | 1.15 |
| Year-End Price | 340.80 | 316.80 | 180.00 | 96.00 | 10.88 | 2.89 | 1.15 |
SOLIGENIX, INC. passes 0 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 11.6%.
SOLIGENIX, INC. (SNGX) has a 5-year average return on invested capital (ROIC) of -83.1%. This is below average and may indicate limited pricing power.
SOLIGENIX, INC. (SNGX) has a market capitalization of $12M. It is classified as a small-cap stock.
SOLIGENIX, INC. (SNGX) does not currently pay a regular dividend.
SOLIGENIX, INC. (SNGX) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
SOLIGENIX, INC. (SNGX) generated $-8 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
SOLIGENIX, INC. (SNGX) has a debt-to-equity ratio of 0.00. This indicates a conservatively financed balance sheet.
SOLIGENIX, INC. (SNGX) reported earnings per share (EPS) of $-4.98 in its most recent fiscal year.
SOLIGENIX, INC. (SNGX) has a return on equity (ROE) of -249.0%. A negative ROE may indicate losses or negative equity.
SOLIGENIX, INC. (SNGX) has a 5-year average gross margin of 11.6%. This lower margin is typical of capital-intensive or commodity businesses.
The Ledger Terminal provides 6 years of financial data for SOLIGENIX, INC. (SNGX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
SOLIGENIX, INC. (SNGX) has a book value per share of $2.48, based on its most recent annual SEC filing.